Abstract Details
|
Danielle A. Griffin
PRESENTER |
Ms. Griffin has stock in Sarepta Therapeutics. Ms. Griffin has received intellectual property interests from a discovery or technology relating to health care. |
| Eric Pozsgai | Eric Pozsgai has received personal compensation for serving as an employee of Sarepta Therapeutics. Eric Pozsgai has received stock or an ownership interest from Sarepta Therapeutics. |
| William Grose | No disclosure on file |
| Kristin N. Heller, PhD (Nationwide Children's Hospital) | No disclosure on file |
| Jerry R. Mendell, MD, FAAN (The Research Institute at Nationwide Children's Hospital) | Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta. |
| Zarife F. Sahenk, MD, PhD, FAAN (The Research Institute at Nationwide Childrens.org) | Dr. Sahenk has nothing to disclose. |
| Jimmy A. Schiemann (Takeda) | No disclosure on file |
| Louise R. Rodino-Klapac (Sarepta Therapeutics) | Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care. |